H. D. Smith names new EVP for specialty arm Smith Medical Partners
SPRINGFIELD, Ill. — H. D. Smith on Monday announced the appointment of Tim Booth to EVP, Smith Medical Partners. Smith Medical Partners is a wholly owned subsidiary of H. D. Smith focused on specialty pharmaceutical distribution and services, and is part of the newly formed H. D. Smith Specialty Solutions group.
"Smith Medical Partners, as part of H. D. Smith Specialty Solutions, is committed to providing customers with a true end-to-end service value chain – enabling healthcare providers to deliver lifesaving medicines and supplies to patients with specialized needs," stated Joe Conda, president, H. D. Smith Specialty Solutions. "Tim’s knowledge and senior-level industry relationships will help us continue the transformation of H. D. Smith from a strictly wholesale distribution company to a services- and solutions-based company that supports the independent community pharmacies, local institutions and specialized care centers that make up the backbone of the U.S. health system."
"Tim’s appointment to executive vice president of Smith Medical Partners is a clear reflection of our commitment to align H. D. Smith talent to best meet customer and partner needs," added Dale Smith, chairman and CEO H. D. Smith. "He is a powerful leader whose strong background in operations, strategic planning, regulatory and compliance will serve Smith Medical Partners and its customers well, as we continue the expansion of our Specialty Solutions operation."
In his new role, Booth will oversee Smith Medical Partners’ operations, sales and company management and be responsible for achieving specific goals for the organization.
Booth most recently served as corporate VP of H. D. Smith’s Home Healthcare operations. He joined H. D. Smith in 2012 as corporate VP Home Healthcare where he was credited with improving the company’s home healthcare profit through vendor and customer relationships, sales leadership and distribution center coordination.
Prior to joining H. D. Smith, Booth was president of RxPak, a division of The McKesson Corporation, specializing in the financial and operational responsibilities of its pharmaceutical packaging division. His experience also includes serving as president/CEO of PrePak Holdings, a private equity-owned pharmaceutical packaging contract manufacturing and packaging company.
Booth holds a master’s of business administration degree, with a concentration in international business and finance, from Cleveland State University. He also holds a bachelor’s degree of business administration, with a finance emphasis from the same institution.
Patients taking obesity drug experience improvement in cardiovascular risk factors, study finds
MOUNTAIN VIEW, Calif. — Patients who take a drug for losing weight may experience improvement in multiple cardiovascular disease risk factors, according to a new study.
The study, conducted by researchers at the University of Alabama and published online in the American Journal of Cardiology, examined the use of Vivus’ drug Qsymia (phentermine and topiramate) extended-release capsules, finding that use of the drug led to "significant" improvements in cholesterol, blood pressure and triglycerides in obese and overweight patients, particularly in those who lost 10% or more of their starting weight.
"This provides clear evidence that patients with hypertension or high cholesterol treated with Qsymia for one year experienced significant weight loss and clinically meaningful improvements in their underlying cardiovascular risk factors," director of the University of Alabama’s vascular biology and hypertension program and study investigator Suzanne Oparil said. "The ability to improve underlying risk factors is another reason physicians should proactively discuss the medical treatment of obesity with their patients who have failed lifestyle modification alone."
Study finds men on long-acting opioids have lower testosterone
OAKLAND, Calif. — Men taking long-acting medications for chronic pain are almost five times more likely to have low testosterone levels, according to a new study by Kaiser Permanente.
The study, which the healthcare system called the first to show a significant difference in risk between short-acting and long-acting opioids, appeared in The Clinical Journal of Pain.
The retrospective study enrolled 81 men between the ages of 26 years and 79 years, who were seen in the chronic-pain clinic at Kaiser Permanente’s Santa Rosa Medical Center in California between January 2009 and June 2010. All study participants had been on a stable dose of an opioid for at least three months. Comparing the use of short-acting opioids, which immediately release the medication when taken, and long-acting opioids, which release it slowly, the study found that 74% of the men on the long-acting opioids had low testosterone, compared with 34% of those on the short-acting opioids.
"For years, doctors have been encouraged to prescribe long-acting opioids rather than short-acting opioids because we believe they were safer, had less abuse potential and offered more consistent pain control, but no study has ever been able to support this practice," Santa Rosa Medical Center anesthesiologist Andrea Rubinstein said.
A larger retrospective study of more than 1,500 male pain patients is currently underway, Kaiser Permanente said.